Jefferies Upgrades Minerva Neurosciences to Buy, Raises Price Target to $10

Jefferies analyst Biren Amin upgrades Minerva Neurosciences (NASDAQ:NERV) from Hold to Buy and raises the price target from $7.5 to $10.